Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TK1 | P04183 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Bromouracil SCHEMBL4201154 | 0.85 | PYGM (0.39) | ATAD2GAAMAPTTK1ALDH1A1 | |
| SCHEMBL4284709 | 0.84 | DPYD (0.50) | GAAMAPTTK1 | |
| Fluorouracil SCHEMBL4289411 | 0.84 | LMNA (0.50) | GAAMAPTTK1ALDH1A1 | |
| Ribose (Furanose) SCHEMBL1851842 | 0.80 | ATAD2 (0.54) | ATAD2ALDH1A1 | |
| Ribose (Furanose) SCHEMBL5521544 | 0.80 | ATAD2 (0.54) | ATAD2ALDH1A1 | |
| D-Galactose SCHEMBL16581344 | 0.78 | ATAD2 (0.53) | ATAD2ALDH1A1 | |
| Dextrose SCHEMBL6692229 | 0.78 | ATAD2 (0.53) | ATAD2ALDH1A1 | |
| SCHEMBL4205792 | 0.77 | MPO (0.32) | TK1 | |
| Uracil SCHEMBL4193859 | 0.76 | CRBN (0.47) | GAAALDH1A1 | |
| SCHEMBL4190649 | 0.75 | MMP2 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5397706-A | Serum-free basal and culture medium for hematopoietic and leukemia cells | CORREA PAULO N (CA) | 1995-03-14 | — | — | US | claimed |
| WO-1993009220-A1 | CELL CULTURE MEDIUM | CORREA PAULO N (CA) | 1993-05-13 | — | — | WO | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | claimed |
| EP-3533863-B1 | PROCESS FOR REDUCING UNWANTED CULTURE BYPRODUCTS IN CELL CULTURE MEDIUM | SAMSUNG BIOEPIS CO LTD (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-20230203554-A1 | PROCESS FOR REDUCING UNWANTED CULTURE BYPRODUCTS IN CELL CULTURE MEDIUM | SAMSUNG BIOEPIS CO LTD (KR) | 2023-06-29 | — | — | US | disclosed |
| EP-3533863-A1 | PROCESS FOR REDUCING UNWANTED CULTURE BYPRODUCTS IN CELL CULTURE MEDIUM | Samsung Bioepis Co., Ltd. (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-8754058-B2 | Inhibitors of FAM3B gene, inhibitor compositions, inhibiting methods and applications of inhibitors in preparing pharmaceuticals | Suzhou Ribo Life Science Company, Ltd. (CN) | 2014-06-17 | — | — | US | disclosed |
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | Suzhou Ribo Life Science Co., Ltd. (CN) | 2013-02-21 | — | — | US | disclosed |
| CN-102471300-A | Compositions and methods for enhancing viral potency | OTTAWA HOSPITAL RES INST | 2012-05-23 | — | — | CN | disclosed |
| US-7608402-B2 | DNA methylation specific signal amplification | LI WEIWEI | 2009-10-27 | — | — | US | disclosed |
| US-20090181373-A1 | DNA methylation specific signal amplification | LI WEIWEI | 2009-07-16 | — | — | US | disclosed |
| US-5397706-A | Serum-free basal and culture medium for hematopoietic and leukemia cells | CORREA PAULO N (CA) | 1995-03-14 | — | — | US | disclosed |
| WO-1993009220-A1 | CELL CULTURE MEDIUM | CORREA PAULO N (CA) | 1993-05-13 | — | — | WO | disclosed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | disclosed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | disclosed |
| CN-85107547-A | Microchemiluminescent detection system | — | 1987-04-15 | — | — | CN | disclosed |
| EP-0122151-A2 | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | disclosed |
| US-4404368-A | Lyophilized phosphorylated nucleosides | ENS BIOLOGICALS INC. (CA) | 1983-09-13 | — | — | US | disclosed |
| EP-0058563-A1 | Lyophilized phosphorylated nucleosides | ens BIO LOGICALS INC. (CA) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | FAM222B, FAM162A, FAM20C | ATAD2 865/4885GAA 304/4885MAPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.